Post sponsored by

MIL OSI Translation. Region: Germany / Deutschland –

Source: Charite – Universitatsmedizin Berlin Joint press release of the Charité and the Berlin Institute of Health On January 1, 2021, the Berlin Institute of Health (BIH) will become the translational research area of ​​the Charité – Universitätsmedizin Berlin and will form its third pillar alongside the hospital and medical faculty. The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) becomes a privileged partner of the BIH. The three institutions are thus taking the final step in the implementation of the administrative agreement between the Federal Government and the State of Berlin, which Federal Research Minister Anja Karliczek and Berlin’s Governing Mayor and Senator for Science Michael Müller had already signed in July 2019. The federal government is structurally involved in a university medical facility for the first time through this innovative science policy initiative and has a seat on the Charité supervisory board. Federal Research Minister Anja Karliczek explains: “At the turn of the year, the integration of BIH into the Charité will finally become a reality. We have great hopes for this new structure, which closely links research and clinical practice. I would like to thank everyone involved for their commitment to the implementation over the past months. We are all very excited about the research activities. I wish the BIH, the Charité and the Max Delbrück Center every success in their collaboration. I am convinced that this alliance will develop a radiance for translational biomedical research nationally and internationally. “The Governing Mayor and Senator for Science of Berlin Michael Müller says:” The integration of the BIH into the Charité is a great benefit for medical research, for Berlin as a health location and above all for patients throughout Germany. The way there was not always easy, but the goal was always the right one. I would therefore like to thank everyone who has brought this process to a successful conclusion in the past few months. The fact that the federal government is so strongly committed to a state institution and that we pull together is not a matter of course and a vote of confidence in the outstanding work that is being done at the Charité, the BIH and the MDC. ” Dr. Christopher Baum will in future represent the BIH as board member of the translation research department on the board of the Charité. He welcomes the integration because he is convinced that translational medicine thrives on the close exchange between patient care and research. “We belong together and at the same time we preserve our special identity and purpose. Together we act for the patients who urgently need new medical approaches. Both perspectives, that of current health care reality and that of medicine of the future, stimulate our scientific work. ”Prof. Dr. Heyo K. Kroemer, CEO of the Charité, welcomes the BIH as the third pillar for translational research at the Charité: “I am looking forward to working with the BIH to further advance the translation of research results into clinical application in our patients and the to use possible synergies between Charité and BIH profitably. But integration is not only of great importance to us. Rather, it can serve as a blueprint for future cooperation between the federal and state governments in research funding. A special thank you goes to Axel Pries, who has brought this project forward significantly and with great commitment over the past few years. ”Prof. Dr. Axel Radlach Pries, Dean of the Charité, held the office of CEO of the BIH for two years until the beginning of October 2020. He looks back with joy on the past and with many expectations on the coming phase: “The integration of the BIH into the Charité with the privileged partnership of the MDC required extensive coordination between our facilities. The administrative agreement can now be implemented as planned. At the same time, the BIH has set up new structures, developed very dynamically and successfully brought outstanding scientists to Berlin. So I have no doubt about the future success of the BIH as the third pillar of the Charité. ”The second founding institution of the BIH, the MDC, will become a privileged partner of the BIH from 2021. Prof. Dr. Thomas Sommer, Scientific Director of the MDC (acting), says: “I am very much looking forward to the close cooperation. The BIH as a bridge between basic research and clinic is the ideal partner for us in Berlin. Our scientists bring their innovative strength to vascular biomedicine, single cell analysis and technology platforms. MDC, BIH and Charité will advance the idea of ​​a joint research space for translation for the benefit of patients. Our close connection means a boost for Berlin as a health location. ”The BIH, founded in 2013, has the mission of transferring results from basic research to bedside applications and, conversely, of converting observations from everyday clinical practice into research ideas. The close cooperation between BIH, Charité and MDC has also been essential in the past. For example, the Charité and BIH jointly operate the Clinical Study Center (CSC) in order to significantly improve the quality of all clinical studies, and together with other partners have set up the BIH Charité Clinician Scientist Program to train a new generation of translationally trained scientists. The technology transfer BIH Innovations is also jointly maintained. During the corona pandemic, BIH scientists, together with researchers and doctors from the Charité, achieved valuable results on the SARS-CoV-2 virus and the COVID-19 disease and published them in a high-ranking manner. “The trusting cooperation between Charité and BIH and the MDC are not only tried and tested, they also work extremely well, ”says Prof. Kroemer. “The successful application of our three houses for a location for the National Center for Tumor Diseases in Berlin is an expression of this. Now it is a matter of further optimizing the framework conditions in order to create the best conditions for translational research. ”With the integration into the Charité, the federal government has given the BIH a mandate to support promising translation projects nationwide. “We are happy to accept this order,” says Prof. Baum. “Here I see our contribution to the rare and complex diseases for which we want to specifically expand the possibilities of university medicine.” In addition, Baum wants to develop translation into an exact science, the success of which is quantitative, reproducible and objectively measurable. “This will be necessary in order to identify those projects that are most promising and to initiate the best possible next steps.” The BIH Quest Center has already done decisive preparatory work here to increase the quality of biomedical research. The BIH has in common launched three focus areas with Charité and MDC, in which excellent research approaches are combined with clinical expertise. In the area of ​​single cell technologies for personalized medicine, innovative single cell technologies are to be used for clinical questions. The focus area Translational Vascular Biomedicine deals with the smallest blood vessels, the malfunction of which is responsible for many common diseases. With the complete takeover of the BCRT, the BIH Center for Regenerative Medicine, from 2021 as well as the cooperation with the German Stem Cell Network GSCN, the BIH will research and apply results achieved in particular in the field of stem cell research and ATMPs, innovative drugs and medical products With the integration of the BIH into the Charité, the number of scientific groups that belong to the BIH will increase from the current 43 to 58, with 71 groups expected by the end of 2021. The approximately 400 employees of the BIH will then be spread over several locations: From March onwards, the groups dealing with vascular biomedicine are to move into the Käthe-Beutler-Haus in Berlin-Buch, in the immediate vicinity of the privileged partner MDC. In the building named after a Jewish pediatrician and researcher, BIH and MDC groups work together under one roof. In the ATIZ outpatient, translation and innovation center in Berlin-Mitte, which celebrated the topping-out ceremony in July 2020 and is due to be completed in early 2022, the groups on digital medicine, such as the BIH-Digital Health Center, and other research teams will have experts the Charité and the joint Clinical Study Center will be housed. The single cells focus area is also located in Berlin-Mitte, at the Berlin Institute for Medical Systems Biology (BIMSB) of the MDC. The research groups in regenerative medicine will primarily conduct research on the Charité Campus Virchow-Klinikum (CVK) in Berlin-Wedding in the rooms of the BCRT. The BIH’s Digital Health Accelerator will move into new offices at the circus in Berlin-Mitte at the beginning of 2021. About Charité – Universitätsmedizin Berlin Charité – Universitätsmedizin Berlin is one of the largest university hospitals with around 100 clinics and institutes on 4 campuses and 3,001 beds Europe. Research, teaching and health care are closely networked here. With an average of around 15,500 employees across the Charité and 18,700 across the Group from over 100 nations, the Berlin University Medical Center is one of the capital’s largest employers. 4,553 of the employees worked in the care sector and 4,454 in the scientific and medical sector. Last year, the Charité treated 154,261 fully and part-time inpatient cases and 700,819 outpatient cases. In 2019 the Charité achieved total income of around 2.0 billion euros, including third-party funding and investment grants. With the 179.1 million euros raised in third-party funding, the Charité set a new record. At the medical faculty, which is one of the largest in Germany, more than 8,000 students are trained in human medicine, dentistry and health sciences. In addition, there are 644 training positions in 9 health professions. About the Berlin Institute of Health (BIH) The mission of the Berlin Institute of Health (BIH) is medical translation: Findings from biomedical research are translated into new approaches for personalized prediction, prevention, diagnostics and therapy, and vice versa Observations in everyday clinical practice lead to new research ideas. The aim is to achieve a relevant medical benefit for patients and citizens. To this end, the BIH is establishing a comprehensive translational ecosystem, relies on a cross-organ understanding of health and disease and promotes a translational cultural change in biomedical research. The BIH was founded in 2013 and is funded 90 percent by the Federal Ministry of Education and Research (BMBF) and ten percent by the State of Berlin. The founding institutions Charité – Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) are independent member bodies in the BIH. From 2021 the BIH will be integrated into the Charité as a so-called third pillar, the MDC will be a privileged partner of the BIH.

LinksPress release on the signing of the administrative agreement of July 10, 2019 Information on the ATIZ building with a short film about the topping-out ceremonyInformation on the Käthe-Beutler-HausInformation on Käthe BeutlerProf. Baum on his plans in Berlin (BIH podcast) Prof. Baum on the integration of the BIH into the Charité (BIH podcast) BIH Center for Regenerative TherapiesGerman stem cell network GSCN

Contact Manuela Zingl Company spokeswoman Charité – Universitätsmedizin Berlint: +49 30 450 570 400 Dr. Stefanie SeltmannHead of Communication & MarketingBerlin Institute of HealthT: +49 30 450 543019

Back to overview


EDITOR’S NOTE: This article is a translation. Apologies should the grammar and / or sentence structure not be perfect.

MIL Translation OSI